Potential specific therapies in COVID-19

Muhammad Hamdan Gul, Zin Mar Htun, Nauman Shaukat, Muhammad Imran and Ahmad Khan

Abstract: COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection.

The reviews of this paper are available via the supplemental material section.

Keywords: convalescent blood products, coronavirus, corticosteroids convalescent sera, favipiravir, IL–6, interferons, lopinavir-ritonavir, MERS, novel virus, remdesivir, ribavirin, SARS-COV-1, tocilizumab

Received: 25 March 2020; revised manuscript accepted: 20 April 2020.

Introduction
As the COVID-19 pandemic spreads throughout the world, there is an urgent call for effective treatments. We review the potential therapies for COVID-19 with an emphasis on experience with severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) (COVID-19 has about 80% nucleotide similarity to SARS-COV-1) and other viruses. Convalescent blood products, other antivirals such as chloroquine phosphate, hydroxychloroquine (HCQ), favipiravir, remdesivir, interferon, and ribavirin, and immune modulators such as tocilizumab, are considered as therapies for the novel coronavirus COVID-19. Evidence has accumulated against other medications such as lopinavir-ritonavir and steroids, which are likely not beneficial in COVID-19 treatment. Here, we review the evidence that has led to the interest in these therapies against the novel COVID-19 infection (Table 1).

Convalescent blood products
Convalescent blood products are derived from the serum or whole blood of patients who have recovered from the infection and are the source of antibodies that can neutralize the pathogens. The various forms of convalescent blood products include convalescent serum or whole blood, pooled human immunoglobulin, high titer immunoglobulin, and polyclonal or monoclonal antibodies. In a meta-analysis that included eight studies with 1703 patients infected with Spanish influenza, convalescent sera were effective in reducing mortality (16% versus 37%). In another meta-analysis that included 32 studies with SARS-COV-1 and severe influenza, convalescent plasma transfusion was associated with a statistically significant decrease in mortality [odds ratio (OR), 0.25; 95% confidence interval (CI), 0.14–0.45]. In a non-randomized observational study in Hong Kong, 80 SARS-COV-1 patients were treated with convalescent plasma. Higher day 22 discharge rate was observed in patients who were treated with convalescent plasma prior to day 14 of illness (58.3% versus 15.6%; p < 0.001). The mortality rates in the two groups were 6.3% and 21.9%, respectively (p = 0.08). In another retrospective, non-randomized study on 40 SARS-COV-1 patients who did not improve with...
**Table 1.** Summary of the potential specific therapies of COVID-19.

| Medication                  | Dose (for CrCl > 60), Route | Safety, adverse events                                                                 | Human clinical studies in viruses other than COVID-19                                                                 | Human clinical studies in COVID-19                                                                 |
|-----------------------------|-----------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Convalescent blood products | The dose is adjudicated based on the titer of antibody in the convalescent serum | Well tolerated, antibody-dependent enhancement of infection; susceptibility to other viral infections, transfusion-related lung injury, thrombotic events | Mortality improvement with convalescent sera in Spanish flu, H1N1 flu infection, and no mortality benefit in Ebola infection. Monoclonal antibodies mAb114 and REGN-EB3 were superior to remdesivir in reducing mortality in Ebola infection. | In a case-series of five critically ill intubated, convalescent plasma transfusion was associated with clinical improvement in all five patients, a decrease in viral load, resolution of ARDS in four patients, extubation and discharge in three patients. In another study of 10 severe COVID-19 patients, the transfusion led to the improvement in clinical symptoms in 3 days, and the disappearance of viremia along with radiological improvement in 7 days. |
| Chloroquine phosphate/HCQ   | No optimal dosage defined. Chloroquine 500 mg oral daily (South Korea) 5–10 days, HCQ 600mg daily 5–10 days HCQ 400mg daily for 5 days | Diarrhea, QT prolongation Monitoring for QT prolongation and cardiovascular effects, especially if combined with azithromycin. A rare side effect of retinopathy in the long term and high dose use. HCQ is the less toxic form of chloroquine phosphate. | Two clinical trials of HIV-1 at 800 mg/day HCQ dose decreased viral load and IL-6. Another clinical trial in HIV 1 patients with HCQ 400mg/day did not reduce viral load or change in immune activation | Zhejiang RCT 30 patient, randomized to HCQ + conventional treatment versus conventional treatment; no difference in the nasopharyngeal viral carriage (87% versus 93% on day 7). Wuhan RCT 62 patients, randomized to HCQ versus control; shortened time to clinical recovery and increased resorption of pneumonia in HCQ arm (80.6% versus 54.8%). |
| Favipiravir                  | 1600 mg orally twice a day on the 1st day, 600 mg orally twice a day starting 2nd day onward Duration: 4–7 days | Well tolerated, GI side effects, transaminitis, increased uric acid, psychiatric symptoms | The nonrandomized clinical trial in EBOLA virus patients showed a lack of efficacy in patients with high viremia; however, it may be useful in patients with relatively low viral load | Preliminary non-peer reviewed preprinted results from a randomized clinical trial on 240 patients suggests improved 7-day clinical recovery and more effective reduction in the incidence of fever and cough compared with arbidol; however, no difference in oxygen requirement or non-invasive ventilation rate noted. |
| Remdesivir                  | 200 mg IV on the first day followed by 100 mg Duration: 5–10 days | Concern for GI side effect; nausea, vomiting, diarrhea, and elevated transaminases | Randomized clinical trial in Ebola infection did not show any mortality benefit. | The compassionate use of remdesivir on 61 patients, clinical improvement was observed in 68% (36 out of 53) of the patients. RCT results awaited |
| Lopinavir/Ritonavir          | 400/100mg oral two times daily (HIV dose) | Diarrhea, GI disturbances, rash | Favorable clinical response in a non-randomized clinical trial on SARS-COV 1 patients | Data from the randomized clinical trial did not show any benefit |

(Continued)
Medication Dose (for CrCl > 60), Route Safety, adverse events Human clinical studies in viruses other than COVID-19 Human clinical studies in COVID-19

**INF-α-2a and Ribavirin**  Peg INF-alpha-2a; 180 μg subcutaneously per week for 2 weeks Ribavirin 2000 mg orally loading dose then 1200 mg every 8 h for 4 days, then 600 mg PO every 8 h for 4–6 days (dose used for MERS)

- Unfavorable side effect profile: significant depressive symptoms (21–58%), anemia (34%), flu-like symptoms (22%) and GI symptoms (19.4%) 
- In a multicenter observational study of 349 critically ill MERS patients, interferon and ribavirin combination were not associated with any benefit in mortality or viral clearance. A retrospective observational study of 32 MERS patients, mortality with interferon α2a was 85% versus 64% with interferon β1a. Retrospective cohort study 44 MERS patients, interferon-alfa-2a and ribavirin, was associated with improved survival at 14 days but not at 28 days.
- No clinical trial data available

**Corticosteroids**  –  

- Unfavorable side effect profile. Hypertension, hyperglycemia, osteoporosis, psychosis
- Systemic review in SARS-COV-1 reported harm associated with corticosteroids use delayed viral clearance (RCT), psychosis, diabetes, and avascular necrosis. Corticosteroid use was associated with delayed clearance of viral RNA in MERS-CoV infection
- Recommended against use in COVID-19 pneumonia unless indicated for other reasons

**Tocilizumab**  

| Weight | Dose | Elevated liver enzymes | No randomized clinical trial available | A retrospective observational study of 20 patients; 75% of the patients had improvement in oxygen requirement, 90.5% of the patients had radiological improvement on CT scan, CRP decreased significantly, and the lymphocytes count initially decreased and then improved RCT results pending |
|--------|------|------------------------|--------------------------------------|--------------------------------------------------------------------------------------|
| 50–60kg | 400 mg as a single intravenous infusion 60–85 kg: 600 mg as a single intravenous infusion 85 kg: 800 mg as a single intravenous infusion. Repeat the dose in 12 h if no improvement observed | | | |

**Table 1.** (Continued)
ribavirin and 1.5 g pulsed methylprednisolone, the patients were assigned to receive convalescent plasma or further pulsed steroids. Patients who received plasma had shorter hospital stay (adjusted discharge rate 77.8% versus 23%, p = 0.004) and lower mortality (0% versus 23.8%, p < 0.049).35 In the H1N1 influenza pandemic, in a prospective cohort study, treatment with convalescent plasma reduced respiratory viral load and mortality (20% versus 54.8%).36 The convalescent plasma was tested in the Ebola epidemic in a non-randomized study of 84 patients with confirmed Ebola. It did not improve mortality (31% versus 38%, risk difference, −7% points; 95% CI, −18 to 4).4 However, the authors later reported that the titers of anti-Ebola virus antibodies were low in many donations, and that the effectiveness of higher titer antibodies convalescent sera needed to be tested.37 Significant mortality reduction was noted with the use of the monoclonal antibody MAb114 [35.1% versus 49.7% (control), p = 0.007] and the triple monoclonal antibody REGN-AB3 [33.5% versus 51.3% (control), p = 0.002] compared with remdesivir and the control arm in a large randomized clinical trial (RCT) of 681 patients.5 In a case-series of five critically ill intubated patients of COVID-19, who had a high viral load despite being previously treated with various antivirals and steroids, convalescent plasma was administered between 10 and 22 days of admission. The plasma transfusion was associated with clinical improvement, normalization of body temperature, and decrease in viral load in all the patients. Three out of five patients were extubated and discharged.6 In another observational study of 10 severe COVID-19 patients, no serious side-effects were observed with the transfusion of convalescent plasma. The transfusion led to the improvement in clinical symptoms in 3 days and the disappearance of viremia along with radiological improvement in 7 days.7 As the pandemic spreads, convalescent plasma will become an important potential therapy in the treatment of critically ill COVID-19 patients.38 The development of monoclonal and polyclonal antibodies against COVID-19 is an area of active research.38 In a non-peer reviewed pre-printed study from the Netherlands, 47D11 monoclonal antibody was reported to cross-neutralize COVID-19 and SARS-COV-1 by binding to its conserved epitope.39

Convalescent blood products have a long track record of safety; however, they can increase the risk of antibody dependant enhancement of infection (ADE), a phenomenon that can make a person susceptible to infection with other viruses in the presence of antibodies.40 Transfusion-related acute lung injury is also an important risk factor.41 Thrombotic events are rare, but life-threatening complications associated with the transfusion of immunoglobulins.42

**Chloroquine phosphate and HCQ**

Chloroquine phosphate is known to inhibit COVID-19,43 SARS COV-1,44,45 and influenza A and B virus in vitro,46,47 and HIV-1 in patients.48,49 Multiple mechanisms for the antiviral activity of chloroquine have been proposed.50 Increased intracellular zinc levels with zinc ionophores that allow the entry of zinc into the cells have been shown to inhibit RNA-dependent RNA polymerase, an RNA synthesizing enzyme that is critical for the pathogenesis of positive-stranded RNA viruses.51 The intracellular zinc levels are limited primarily by cell membrane structure, as demonstrated by the observation that the addition of zinc chloride only slightly increases intracellular zinc levels.52 Chloroquine, however, is a zinc ionophore and significantly increases intracellular zinc levels.52 In a study reported by the United States Centers for Disease Control and Prevention (CDC), chloroquine appears to interfere with the terminal glycosylation of the angiotensin-converting enzyme 2 (ACE2),45 in addition to the elevation in endosomal pH. ACE2 is the receptor used by the SARS-COV virus to gain entry into cells. The authors concluded that the drug had a possible prophylactic and therapeutic use against SARS-COV-1 cell cultures.45 HCQ is the less toxic derivative of chloroquine. In a recent in vitro study, it was found to be more potent than chloroquine against COVID-19.53

In early clinical trials on HIV-1 patients, the use of HCQ monotherapy at 800 mg/day (equivalent to 500 mg/day chloroquine) resulted in decreased viral load.10,11 However, when it was used at 400 mg/day in another clinical trial,12 it did not show any effect on viral load or immune activation. Attention should be paid to the dosing of HCQ, if used at all, for its antiviral effect.54 Chloroquine failed to improve survival in mice and hamster models infected with Ebola virus.55 In an unpublished news report from China, chloroquine demonstrated encouraging results in COVID-19 patients.36 Based on these preliminary data, chloroquine and HCQ have shown promise in COVID-19 treatment. However, further randomized controlled trials are needed to confirm these findings.
results, a chloroquine sulfate 500 mg twice-daily dose was approved in China,\textsuperscript{57} and chloroquine 500 mg once-daily dose was recommended in South Korea for critically ill or old patients.\textsuperscript{58} In a recent French open-label non-RCT reported by Gautret \textit{et al}., a total of 26 patients receiving HCQ 600 mg daily (6 patients received azithromycin) were compared with 16 control patients. On day 6, all the patients treated with HCQ 600 mg daily and azithromycin did not have the virus detected, \textit{versus} 57.1\% in patients treated with HCQ only and 12.5\% in the control group \((p < 0.005)\).\textsuperscript{8} In a follow-up study by the same French group on 80 COVID-19 patients treated with HCQ and azithromycin without a control arm, the virus was not detected in 83\% on day 7 and 93\% of the patients on day 8.\textsuperscript{59} In another prospective French study, 11 patients were treated with HCQ and azithromycin in the absence of control. Out of 10 patients, 8 had virus detected on days 5 or 6 since initiation of treatment.\textsuperscript{60} Any conclusion from these studies is limited in the absence of a randomized control arm and a lack of clear clinical data. In a randomized control trial from Zhejiang by Chen \textit{et al}., randomized HCQ 400 mg daily for 5 days with conventional treatment to the control arm. No significant difference in nasopharyngeal viral carriage was noted in the two arms on day 7; however, the use of other antivirals may have confounded the results.\textsuperscript{13} The study was not powered to detect any difference in clinical outcomes due to its small sample size. In another RCT from Wuhan, Chen \textit{et al}., randomized HCQ 400 mg daily for 5 days to control arm in 62 COVID-19 patients. Shortened temperature recovery time, cough remission time, and increased absorption of pneumonia (80.6 \textit{versus} 54.8\%) were observed with HCQ treatment.\textsuperscript{8} The data cannot be extrapolated to critically ill patients as only mildly severe COVID-19 (SpO2 > 93\%) patients were recruited in the study.\textsuperscript{61} Large prospective clinical trial data in critically ill COVID-19 patients are awaited.

Chloroquine and HCQ have a good safety profile overall. QT prolongation and cardiovascular effects are clinical concerns with high doses of chloroquine. QT prolongation should be monitored, especially if combining with azithromycin. Another rare side effect noted is retinopathy. However, retinal damage has been observed when chloroquine has been used for years in the treatment of autoimmune conditions.\textsuperscript{62}

**Remdesivir**

Remdesivir is considered one of the promising antivirals in the armamentarium against COVID-19.\textsuperscript{63} Remdisivir (developmental code GS-5734) is an experimental antiviral drug developed by Gilead Sciences. It is a monophosphoramidate prodrug of an adenosine analog. It has a broad spectrum of antiviral \textit{in vitro} activity against other pathogenic RNA viruses, including Middle Eastern Respiratory Syndrome (MERS) and SARS-COV 1, bat COVs viruses. In the \textit{in vitro} system of human airway epithelial cells, remdesivir inhibits MERS-COV and SARS-COV-1. The mouse model of SARS-COV1 demonstrated that the early administration of remdesivir decreased viral load, improved lung function, and the course of clinical disease.\textsuperscript{64} As a nucleotide analog, remdesivir interferes with the activity of RNA polymerase and overcomes the intact exon proofreading ability, thus leading to the premature termination of the transcription.\textsuperscript{65} It was effective in the treatment of Rhesus monkeys against EBOLA virus.\textsuperscript{66} However, when subsequently tested in a clinical trial conducted during the Kivu Ebola epidemic, the monoclonal antibodies mAb114 and REGN-EB3 were superior to remdesivir in reducing mortality.\textsuperscript{9} Remdesivir has been shown to inhibit COVID-19 potently in cell cultures.\textsuperscript{43} In the compassionate use of remdesivir on 61 patients, clinical improvement was observed in 68\% (36 out of 53) of the patients; however, any derivation of a conclusion is limited because of lack of comparator arm and lack of post-treatment data from 7 patients. Hepatic enzyme elevation was observed in 23\% of the patients.\textsuperscript{16} It is currently being tested for efficacy against COVID-19 in clinical trials in China.\textsuperscript{67,68}

**Favipiravir**

Favipiravir (Avigan) developed by Fujifilm Toyama Chemical has been effective against various RNA viruses, including influenza virus, arenaviruses, bunyaviruses, West Nile viruses, yellow fever viruses, and foot and mouth viruses.\textsuperscript{69} It is effective against the H5N1 influenza virus in a mouse model; mice are poorly sensitive to oseltamivir.\textsuperscript{70} Favipiravir is a nucleoside analog that requires intracellular phosphoribosylation to be converted into the active metabolite. The mechanism of action is inhibition of viral RNA-dependent RNA polymerase.\textsuperscript{71} In the non-RCT against EBOLA virus disease, where a historic control arm was used to analyze the results, favipiravir was not
effective as a stand-alone treatment in patients with very high viremia; however, it should be further studied in patients with relatively lower viral loads. Favipiravir was well tolerated in clinical trials. Favipiravir is approved in Japan for the treatment of pandemic influenza infections. Based on its broad-spectrum antiviral effect, favipiravir is thought to be a prime candidate for emerging RNA viruses. The bar for developing resistance against favipiravir is high. In non-peer-reviewed preprinted results from a clinical trial of 240 patients randomized for the use of favipiravir or arbidol on hospitalized SARS-COV-1 patients, favipiravir use was associated with the higher 7-day clinical recovery and more effective reduction in the incidence of fever and cough; however, no difference in oxygen requirement or non-invasive ventilation rate was noticed. Favipiravir use was also associated with increased uric acid, psychiatric symptoms, gastrointestinal (GI) adverse effects, and increased liver function tests in 14% of the patients. These results are reminiscent of favipiravir use in the Ebola epidemic, suggesting that favipiravir may not be as effective in severe cases compared with mild cases of COVID-19.

**Lopinavir–Ritonavir**

Lopinavir is a protease inhibitor that, when combined with ritonavir, improves the mean trough plasma lopinavir concentration. It is approved for the treatment of HIV-infected patients. Adverse effects of lopinavir–ritonavir include diarrhea, GI disturbances, headache, and skin rash. Lopinavir–ritonavir and ribavirin showed an apparent favorable clinical response in 44 SARS-COV-1 patients when compared against 111 historic control ribavirin-treated patients. In a double-blinded RCT on 199 patients infected with COVID-19 in China, lopinavir–ritonavir did not show any benefit beyond standard care (mortality 19.2% versus 25.0%; difference, −5.8 percentage points; 95% CI, −17.3 to 5.7). With these results from the clinical trial, lopinavir–ritonavir use should no longer be considered for the treatment of COVID-19, unless in the context of a clinical trial.

**Interferons and Ribavirin**

Dysregulated immune response, including suppressed levels of interferons, have been observed with the infection of corona viruses. Human recombinant interferon inhibits SARS-COV-1 replication *in vitro*. In a non-human primate model in the common marmoset, the combination of interferon β1b and lopinavir/ritonavir was associated with better outcomes.

Ribavirin has been used in the past for the treatment of respiratory syncytial virus (RSV), Congo hemorrhagic fever, and hepatitis C. Ribavirin is a guanosine analog and interferes with polymerase inhibition, mRNA capping, and lethal mutagenesis. It has also been used in combination with interferon. The combination of interferon-α2b and ribavirin inhibited MERS-COV *in vitro*. In a preliminary uncontrolled study on patients with SARS-COV-1, nine patients received interferon alfacon-1 with corticosteroids, and three patients were transferred to the ICU; however, none died. In a retrospective cohort study of 44 critically ill MERS patients, 24 patients received interferon-alfa-2a and ribavirin; the therapy was associated with improved survival at 14 days but not at 28 days. In another retrospective study of 32 MERS patients, interferon α2a or interferon β1a were used in combination with ribavirin. The mortality rate in patients who received interferon α2a was 85% compared with 64% in those who received interferon β1a. These results did not suggest benefit with interferon and ribavirin since MERS-COV pneumonia mortality was thought to be around 67%. In a multicenter observational study of 349 patients with critically ill MERS patients, 144 patients received interferon and ribavirin. They were not associated with any benefit in mortality or viral clearance.

The combination of interferon-alpha-2a and ribavirin in the clinical trial led to discontinuation of the medication in up to 27% of the patients receiving therapy for a year. Interferon-alpha-2a and ribavirin have an unfavorable adverse effect profile, including significant depressive symptoms (21–58%), anemia (34%), flu-like symptoms (22%), and GI symptoms (19.4%). Based on mostly unfavorable experiences with MERS epidemics and high side-effect profile, the empiric combination should not be advocated in the absence of any clinical trial results on COVID-19.

**Corticosteroids**

The idea of the use of steroids was coined in the treatment of acute respiratory distress in the meta-analysis on the effect of steroids in
SARS-COV-1 by Stockman et al.; 25 studies were inconclusive, and only 4 studies were conclusive, all of which showed harm with the use of steroid.23 Corticosteroids use in the first week were associated with delayed viral clearance in a randomized, double-blind placebo trial.91 The other three studies reported psychosis,25 diabetes,26 and avascular necrosis.27 Corticosteroid use was associated with delayed clearance of viral RNA in MERS-CoV infection.28 In preliminary data from a retrospective cohort study from China in COVID-19, corticosteroids were used more often in patients who died (48%) than in patients who survived (23%), \( p < 0.001 \).92 Based on this evidence, the World Health Organization (WHO) and other experts have recommended against the use of corticosteroid treatment against COVID-19 lung injury unless indicated for other indications.29,30 In the setting of cytokine storm, immunosuppression with steroids, if tocilizumab is not available, maybe considered.93

**Tocilizumab**

Tocilizumab is a humanized monoclonal antibody used in the treatment of rheumatoid arthritis,94 juvenile idiopathic arthritis,95 and cytokine release syndrome.96 Tocilizumab blocks the interleukin-six (IL-6) receptor. IL-6 is a pro-inflammatory cytokine and can be released in response to viral infections.97 In a study on 150 patients from Wuhan, China, IL-6, ferritin, and C reactive protein (CRP) were elevated in patients who died in comparison with those who survived.98 These elevated laboratory markers suggest the possibility of hypercytokinemia in the setting of secondary hemophagocytic lymphohistiocytosis.93 A viral infection is considered to be the most common trigger of secondary hemophagocytic lymphohistiocytosis.99 Reports of the hemophagocytic syndrome have been noted in SARS-COV-1,100 avian influenza,101 and human influenza.102,103 Tocilizumab, approved for cytokine release syndrome, is being tested in a clinical trial from China in COVID-19 patients.104 The use of H score for cytokine storm has been recommended to determine the critical timing of tocilizumab in severe COVID-19 patients.93 In a retrospective observational pre-printed non-peer reviewed study from China, tocilizumab was used in 20 worsening COVID-19 patients; 75% of the patients had improvement in oxygen requirement, 90.5% of the patients had radiological improvement on computed tomography (CT) scan, CRP decreased significantly, and lymphocyte count initially decreased and then improved.31 There was no randomized control arm in the study, a lack of data reported on the important inflammatory markers such as ferritin and IL-6, and only two patients were intubated prior to the use of tocilizumab in the study. These biases limit the derivation of any conclusion from the study. Elevated liver enzymes is a common adverse effect associated with tocilizumab.105 The use of the Janus kinase (JAK) inhibitor baricitinib, which can inhibit clathrin-mediated endocytosis, has also been considered as a potential option for hypercytokinemia.106

**Conclusion**
Convalescent blood products are promising potential therapies for COVID-19. Other antivirals such as chloroquine or HCQ, remdesivir, and immune modulators such as tocilizumab are the other potential therapies for COVID-19 that are being tested in clinical trials. The use of antiretrovirals, such as lopinavir/ritonavir, did not provide any benefit in a RCT. Steroids appear to be harmful based on human experiences with SARS-COV-1 and MERS infection.

**Acknowledgements**
We would like to acknowledge James Sullivan, who helped in the review of the manuscript.

**Author contribution(s)**
Muhammad Hamdan Gul: Conceptualization; Methodology; Writing-original draft; Writing-review & editing.

Zin Mar Htun: Conceptualization; Data curation; Investigation; Writing-original draft; Writing-review & editing.

Nauman Shaukat: Conceptualization; Investigation; Writing-original draft; Writing-review & editing.

Muhammad Imran: Conceptualization; Investigation; Methodology; Writing-review & editing.

Ahmad Khan: Conceptualization; Investigation; Methodology; Writing-original draft; Writing-review & editing.

**Conflict of interest statement**
The authors declare that there is no conflict of interest.
Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Muhammad Hamdan Gul https://orcid.org/0000-0002-7337-3866

Supplemental material
The reviews of this paper are available via the supplemental material section.

References
1. Zhou P, Yang X-L, Wang X-G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020. DOI: 10.1101/2020.01.22.914952.
2. Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599–609.
3. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2014; 211: 80–90.
4. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016; 374: 33–42.
5. Mulangu S, Dodd LE, Davey Jr RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293–2303.
6. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323: 1582–1589.
7. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117: 9490–9496.
8. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Epub ahead of print 17 March 2020. DOI: 10.1016/j.ijantimicag.2020.105949.
9. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020. DOI: 10.1101/2020.03.22.20040758.
10. Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995; 17: 622–636.
11. Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997; 19: 913–923.
12. Paton NI, Goodall RL, Dunn DT, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012; 308: 353–361.
13. CHEN J, LIU D, LIU L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 2020; 49: 0–0.
14. Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv 2020. DOI: 10.1101/2020.03.17.20037432.
15. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with Favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 2016; 13: e1001967-e1001967.
16. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. Epub ahead of print 10 April 2020. DOI: 10.1056/NEJMoa2007016.
17. Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252–256.
18. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. Epub ahead of print 18 March 2020. DOI: 10.1056/NEJMoa2001282.
19. Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome:
a multicenter observational study. Clin Infect Dis 2020; 70: 1837–1844.

20. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-α. CNS Drugs 2005; 19: 105–123.

21. Gaeta GB, Precone DF, Falaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1633–1639.

22. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015; 70: 2129–2132.

23. Stockman LJ, Bellamy R and Garner P. SARS: systematic review of treatment effects. PLoS Med 2006; 3: e343–e343.

24. Sung J, Wu A, Joynt G, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004; 59: 414–420.

25. Lee DT, Wing Y, Leung HC, et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis 2004; 39: 1247–1249.

26. Xiao J, Ma L, Gao J, et al. Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy. Zhonghua Nei Ke Za Zhi 2004; 43: 179–182.

27. Li Y, Wang S, Gao H, et al. Factors of avascular necrosis of femoral head and osteoporosis in SARS patients’ convalescence. Zhonghua Yi Xue Za Zhi 2004; 84: 1348–1353.

28. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018; 197: 757–767.

29. Russell CD, Millar JE and Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395: 473–475.

30. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected, https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed 19 March 2020).

31. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXin 2020; 202003: V1.

32. Khurana S, Suguitan Jr AL, Rivera Y, et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 2009; 6: e1000049.

33. Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016; 14: 152–157.

34. Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44–46.

35. Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10: 676–678.

36. Hung IF, To KK, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52: 447–456.

37. van Giersens J, Edwards T and Baize S. Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies. N Engl J Med 2016; 375: 2307–2309.

38. Chen L, Xiong J, Bao L, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv 2020. DOI: 10.1101/2020.03.11.987958.

39. Wang C, Li W, Drabek D, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020; 94. DOI: 10.1128/JVI.02015-19.

40. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007; 176: 886–891.

41. Menis M, Sridhar G, Selvam N, et al. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008–2011. Am J Hematol 2013; 88: 1035–1040.

42. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269–271.

43. Keyaerts E, Vigen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus (HCoV-229E) by monoclonal antibodies. J Virol 2000; 74: 302–311.

44. Liang W, The Schuyler J, Jaffe JB, et al. Remdesivir and convalescent plasma for COVID-19: a randomized controlled trial. N Engl J Med 2020. DOI: 10.1056/NEJMoa2001033.
coronavirus by chloroquine. *Biochem Biophys Res Commun* 2004; 323: 264–268.

45. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virol J* 2005; 2: 69.

46. Savarino A, Di Trani L, Donatelli I, et al. New insights into the antiviral effects of chloroquine. *Lancet Infect Dis* 2006; 6: 67–69.

47. Shibata M, Aoki H, Tsurumi T, et al. Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. *J Gen Virol* 1983; 64: 1149–1156.

48. Joshi SR, Butala N, Patwardhan MR, et al. Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy. *J Assoc Physicians India* 2004; 52: 597.

49. Savarino A, Boeclaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today's diseases. *Lancet Infect Dis* 2003; 3: 722–727.

50. Devaux CA, Rolain J-M, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents* 2020: 105938.

51. Te Velthuis AJ, van den Worm SH, Sims AC, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog* 2010; 6.

52. Xue J, Moyer A, Peng B, et al. Chloroquine is a zinc ionophore. *PLoS One* 2014; 9.

53. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov* 2020; 6: 16.

54. Savarino A and Shytaj IL. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. *Retrovirology* 2015; 12: 51.

55. Falzarano D, Saffronetz D, Prescott J, et al. Lack of protection against ebola virus from chloroquine in mice and hamsters. *Emerg Infect Dis* 2015; 21: 1065.

56. Gao J, Tian Z and Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *BioScience Trends* 2020; 14: 72–73.

57. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43: 183–188.

58. Sung-sun K. Physicians work out treatment guidelines for coronavirus, http://www.koreabiomed.com/news/articleView. html?id=xno=7428 (2020, accessed 20 March 2020).

59. Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. *Travel Med Infect Dis*. Epub ahead of print 11 April 2020. DOI: 10.1016/j.tmaid.2020.101663.

60. Molina JM, Delaughter C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Med Mal Infect*. Epub ahead of print 30 March 2020. DOI: 10.1016/j.medmal.2020.03.006.

61. Taccone FS, Gorham J and Vincent J-L. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. *Lancet Respir Med*. Epub ahead of print 15 April 2020. DOI: 10.1016/j.l金银.2020.03.0172-7.

62. Marks JS. Chloroquine retinopathy: is there a safe daily dose? *Ann Rheum Dis* 1982; 41: 52–58.

63. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. *Antimicrob Agents Chemotherapy* 2020; 64. pii: e00399-20.

64. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* 2017; 9: eaal3653.

65. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *MBio* 2018; 9: e00221-00218.

66. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature* 2016; 531: 381–385.

67. Cao B. Severe 2019-nCoV remdesivir RCT - Full Text View - ClinicalTrials.gov,
68. Cao B. Mild/moderate 2019-nCoV remdesivir. https://clinicaltrials.gov/ct2/show/NCT04257656 (2020, accessed 3/18/2020).

69. Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. *Antiviral Res* 2009; 82: 95–102.

70. Sidwell RW, Barnard DL, Day CW, et al. Lopinavir–Ritonavir. *J Antimicrob Chemother* 2003; 362: 293–294.

71. Jin Z, Smith LK, Rajwanshi VK, et al. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. *PLoS One* 2013; 8: e68347–e68347.

72. Delang L, Abdelnabi R and Neyts J. Favipiravir. *Antiviral Res* 2019; 117: 1–17.

73. Chan JF-W, Yao Y, Yeung M-L, et al. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). *Virology* 2004; 329: 11–17.

74. Chen YY, Chen FY, Chien YJ, et al. Interferon-gamma and interleukin-4 downregulate γBL. Interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. *J Infect Dis* 2015; 212: 1904–1913.

75. Mardani M, Jahromi MK, Naieni KH, et al. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. *Clin Infect Dis* 2003; 36: 1613–1618.

76. Bodenheimer Jr HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology* 1997; 26: 473–477.

77. Falzarano D, De Wit E, Martellaro C, et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. *Sci Rep* 2013; 3: 1686.

78. Channappanavar R, Fehr Anthony R, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. *Cell Host Microbe* 2016; 19: 181–193.
chronic infection with hepatitis C virus. *Lancet* 1998; 352: 1426–1432.

91. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *J Clin Virol* 2004; 31: 304–309.

92. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. Epub ahead of print 11 March 2020. DOI: 10.1016/S0140-6736(20)30566-3.

93. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. Epub ahead of print 16 March 2020. DOI: 10.1016/S0140-6736(20)30628-0.

94. Singh JA, Beg S and Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. *J Rheumatol* 2011; 38: 10–20.

95. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. *N Engl J Med* 2012; 367: 2385–2395.

96. Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. *Oncologist* 2018; 23: 943.

97. Frei K, Malipiero UV, Leist TP, et al. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. *Eur J Immunol* 1989; 19: 689–694.

98. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. Epub ahead of print 3 March 2020. DOI: 10.1007/s00134-020-05991-x.

99. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. *Lancet* 2014; 383: 1503–1516.

100. Ng W-F, To K-F, Lam WW, et al. The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1—a review. *Hum Pathol* 2006; 37: 381–390.

101. To KF, Chan PK, Chan KE, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. *J Med Virol* 2001; 63: 242–246.

102. Potter M, Foot A and Oakhill A. Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia. *J Clin Pathol* 1991; 44: 297–299.

103. Mou SS, Nakagawa TA, Riemer EC, et al. Hemophagocytic lymphohistiocytosis complicating influenza A infection. *Pediatrics* 2006; 118: e216–e219.

104. Wang D. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19), http://www.chictr.org.cn/showprojen.aspx?proj=49409 (2020, accessed 21 March 2020).

105. Bannwarth B and Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. *Expert Opin Drug Saf* 2011; 10: 123–131.

106. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis*. Epub ahead of print 27 February 2020. DOI: 10.1016/S1473-3099(20)30132-8.